This is the story of how pioneering research has developed a diagnostic aid helping healthcare professionals on the diagnostic pathway of significant coronary artery disease.
The Acarix Story
Endorsement from ACC.
Acarix Inc. established.
CPT III granted by AMA.
Commercialization agreement with Proximo Medical.
First patients and billing in process.
FDA De Novo Clearance.
Enrolment in Dan-NICADII begins.
Enrolment in Seismo begins.
In commercial use. CADScor®System tests have diagnosed more than 1,000 patients.
Direct sales force in place in Germany, Sweden and Denmark.
First sales in Germany, Sweden, Denmark and Austria.
The CADScor®System transitions from prototype to production of the final product.
Registration of the major Dan-NICAD study comprising 1,675 patients is completed.
Strategic investor Puhua Jingxin agrees on a major investment and discusses collaboration on the Chinese market.
The CADScor®System receives regulatory approval in Canada.
Completed IPO of new shares and listing on Nasdaq First North Premier Stockholm.
The CADScor®System receives its CE marking and is ready for commercialization in Europe.
A new share issue of MDKK 18.7 is carried out.
A new share issue of MDKK 27 is carried out.
Acarix completes the registry study of high-risk groups for CAD – AC003.
Sunstone Capital, SEED Capital and Seventure invest a total of MDKK 21 in the company.
The first prototype is completed and CAD – CP002 studies are conducted on high-risk groups.
Acarix receives MDKK 55.3 in funding from the Market Development Fund in Denmark.
The project is turned into a separate company, and Acarix A/S is founded. Coloplast, Aalborg University and the individual founders are shareholders.
The project receives MDKK 6.8 in funding from Højteknologifonden (the High Tech Fund) in Denmark.
The technology developed at Aalborg University receives the Medicoprisen award in Denmark and is incubated in the Coloplast Innovation Center.